echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Submission of Marketing Application for Radioimmunotherapy for the Treatment of Neuroblastoma in Children

    Submission of Marketing Application for Radioimmunotherapy for the Treatment of Neuroblastoma in Children

    • Last Update: 2022-04-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Y-mAbs Therapeutics announced today that it has completed the submission of a Biologics License Application (BLA) to the U.


    Omburtamab is an investigational monoclonal antibody targeting B7-H3, an immune checkpoint molecule widely expressed in tumor cells of several cancer types


    This submission is based on safety and efficacy results from a pivotal Phase 2 clinical trial


    Image source: Y-mAbs official website

    "We believe this radioimmunotherapy can potentially address the significant unmet need in children with neuroblastoma with CNS/leptomeningeal metastases," said Dr.


    References:

    [1] Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.